Lates News

Every Economic AI express news, Tianfeng Securities released a research report on May 25, giving a buy rating to Hengrui Medicine (600276.SH). The rating reasons mainly include: 1) stable operation, slight decrease in sales expense ratio, increase in research and development expense ratio; 2) high-speed growth in innovative drug revenue, increasing number of new listed projects in the next three years; 3) continuous realization of research and development, abundant reserves of new products in multiple fields in China, continuous granting of overseas equity, it has become an important profit contribution project. (Daily Economic News)